Background illustration for clinical trials search

Merck Clinical Trials

Find clinical trials for Merck. Search for Merck clinical trials in different cities and states across the United States.

Filter

A Study to Compare Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) Versus Pembrolizumab Alone as Treatment in Participants With Mismatch Repair Proficient Endometrial Cancer (MK-2870-033/TroFuse-033/GOG-3119/ENGOT-en29)

for
Endometrial Cancer
Location: St. John's, Scarborough ME, Boston MA, Providence RI,
Sponsor: Merck Sharp & Dohme LLC

Sex: Female

Age: 18+

Code: NCT06952504

Phase 3, Recruiting

A Clinical Study of Patritumab Deruxtecan to Treat Breast Cancer (MK-1022-016)

for
Breast Neoplasms
Location: Moncton, Westbury NY, Jamaica NY, Hackensack NJ,
Sponsor: Merck Sharp & Dohme LLC

Sex: All

Age: 18+

Code: NCT07060807

Phase 3, Recruiting

A Clinical Study of Zilovertamab Vedotin (MK-2140) Plus Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Polatuzumab Vedotin Plus R-CHP in People With Diffuse Large B-cell Lymphoma (DLBCL) (MK-2140-011/waveLINE-011)

for
Lymphoma, Large B-Cell, Diffuse
Location: Boston MA, Westbury NY, Mineola NY, New York NY,
Sponsor: Merck Sharp & Dohme LLC

Sex: All

Age: 18+

Code: NCT06890884

Phase 2, Recruiting

A Clinical Study of Gocatamig (MK-6070) and Infinatamab Deruxtecan (MK-2400) in People With Small Cell Lung Cancer (MK-6070-003)

for
Small Cell Lung Cancer Extensive Stage
Location: Hackensack NJ, Charlottesville VA, Orlando FL,
Sponsor: Merck Sharp & Dohme LLC

Sex: All

Age: 18+

Code: NCT07227597

Phase 1, Phase 2, Recruiting

A Clinical Study of MK-1084 With Other Treatments for Non-small Cell Lung Cancer (MK-3475-01F)

for
Lung Neoplasm Malignant
Location: Clermont FL, Chicago IL, Portland OR
Sponsor: Merck Sharp & Dohme LLC

Sex: All

Age: 18+

Code: NCT07286149

Phase 1, Phase 2, Recruiting

Interested in new trials?

Get alerts for new trials in your area by subscribing now

Subscriber Image

Efficacy and Safety of Nemtabrutinib (MK-1026) in Participants With Hematologic Malignancies (MK-1026-003)

for
Hematologic Malignancies, Waldenstroms Macroglobulinaemia,
Location: Hackensack NJ, East Brunswick NJ, Montreal, Ottawa,
Sponsor: Merck Sharp & Dohme LLC

Sex: All

Age: 18+

Code: NCT04728893

Phase 2, Recruiting

A Study of Nemtabrutinib Plus Venetoclax vs Venetoclax + Rituximab (VR) in Second-line (2L) + Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) (MK-1026-010/BELLWAVE-010).

for
Leukemia, Lymphocytic, Chronic, B-Cell,
Location: Moncton, Sherbrooke, Albany NY, Morristown NJ,
Sponsor: Merck Sharp & Dohme LLC

Sex: All

Age: 18+

Code: NCT05947851

Phase 3, Recruiting

A Study to Evaluate Zilovertamab Vedotin (MK-2140) Combination With Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Previously Untreated DLBCL (MK-2140-010)

for
Diffuse Large B-Cell Lymphoma
Location: Halifax, Shirley NY, New York NY, Belleville NJ,
Sponsor: Merck Sharp & Dohme LLC

Sex: All

Age: 18+

Code: NCT06717347

Phase 3, Recruiting

A Clinical Study of Raludotatug Deruxtecan in People With Ovarian Cancer (MK-5909-003).

for
Ovarian Cancer Recurrent
Location: Boston MA, New Haven CT, New York NY, Montreal,
Sponsor: Merck Sharp & Dohme LLC

Sex: Female

Age: 18+

Code: NCT06843447

Phase 1, Phase 2, Recruiting

A Study of Pembrolizumab With or Without Chemotherapy in Combination With Additional Treatments for Advanced Non-Small Cell Lung Cancer (NSCLC) (MK-3475-01G/KEYMAKER U01)

for
Non-small Cell Lung Cancer
Location: Philadelphia PA, Baltimore MD, Lexington KY, Fargo ND,
Sponsor: Merck Sharp & Dohme LLC

Sex: All

Age: 18+

Code: NCT06731907

Phase 2, Recruiting

Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab Versus Pembrolizumab Alone in Metastatic Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥ 50% (MK-2870-007)

for
Non-small Cell Lung Cancer (NSCLC)
Location: Westbrook ME, Mississauga, Brampton, Jacksonville FL,
Sponsor: Merck Sharp & Dohme LLC

Sex: All

Age: 18+

Code: NCT06170788

Phase 3, Recruiting

Efficacy, Safety, and Pharmacokinetics of Vericiguat in Pediatric Participants With Heart Failure Due to Left Ventricular Systolic Dysfunction (MK-1242-036)

for
Heart Failure, Left Ventricular Systolic Dysfunction
Location: Boston MA, Sherbrooke, The Bronx NY, New York NY,
Sponsor: Merck Sharp & Dohme LLC

Sex: All

Age: 0 - 17

Code: NCT05714085

Phase 2, Phase 3, Recruiting

Substudy 01A: Zilovertamab Vedotin in Pediatric and Young Adult Participants With Hematologic Malignancies or Solid Tumors (MK-9999-01A/LIGHTBEAM-U01)

for
B-cell Acute Lymphoblastic Leukemia,
Location: Boston MA, New Haven CT, Valhalla NY, New York NY,
Sponsor: Merck Sharp & Dohme LLC

Sex: All

Age: 0 - 25

Code: NCT06395103

Phase 1, Phase 2, Recruiting

Long-term Safety and Efficacy Extension Study for Participants With Advanced Tumors Who Are Currently on Treatment or in Follow-up in a Pembrolizumab (MK-3475) Study (MK-3475-587/KEYNOTE-587)

for
Solid Tumors, Hematologic Malignancies
Location: Quebec, Sherbrooke, White Plains NY, New York NY,
Sponsor: Merck Sharp & Dohme LLC

Sex: All

Age: 18+

Code: NCT03486873

Phase 3, Recruiting

Study of Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-3475-158/KEYNOTE-158)

for
Advanced Cancer, Anal Carcinoma, Anal Cancer, Biliary Cancer,
Location: New Brunswick NJ
Sponsor: Merck Sharp & Dohme LLC

Sex: All

Age: 18+

Code: NCT02628067

Phase 2, Recruiting

A Study of Opevesostat (MK-5684) Versus Alternative Next-generation Hormonal Agent (NHA) in Metastatic Castration-resistant Prostate Cancer (mCRPC) Post One NHA (MK-5684-004)

for
Metastatic Castration-resistant Prostate Cancer (mCRPC),
Location: New Haven CT, Quebec, New Brunswick NJ, Montreal,
Sponsor: Merck Sharp & Dohme LLC

Sex: All

Age: 18+

Code: NCT06136650

Phase 3, Recruiting

Merck IIT: RRP Pembro and Lenvatinib

for
Human Papilloma Virus, Recurrent Respiratory Papillomatosis,
Location: New Haven CT
Sponsor: Yale University

Sex: All

Age: 18+

Code: NCT04645602

Phase 2, Recruiting

A Study on the Immune Response and Safety of an Investigational Chickenpox Vaccine and a Marketed Measles, Mumps and Rubella Vaccine When Administered as Intramuscular Injection to Healthy Children 12 to 15 Months of Age

for
Chickenpox
Location: Richmond VA, Coral Gables FL, Miami Lakes FL, Tampa FL,
Sponsor: GlaxoSmithKline

Sex: All

Age: 1

Code: NCT06855160

Phase 3, Recruiting